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Abstract
Background: Women that carry germ-line mutations for BRCA1 or BRCA2  genes are at an
increased risk of developing breast, ovarian and peritoneal cancer. Primary peritoneal carcinoma is
a rare tumour histologically identical to papillary serous ovarian carcinoma. Risk-reducing surgery
in the form of mastectomy and oophorectomy in premenopausal women has been recommended
to prevent breast and ovarian cancer occurrence and decrease the risk of developing primary
peritoneal cancer.
Case presentation: We present a case report of a woman with a strong family history of breast
cancer who underwent risk-reducing surgery in the form of bilateral salpingo-oophorectomy
following a mastectomy for a right-sided breast tumour. Following the finding of a BRCA1 mutation,
a prophylactic left-sided mastectomy was performed. After remaining well for twenty-seven years,
she presented with rectal bleeding and altered bowel habit, and was found to have a secondary
cancer of the sigmoid colon. She was finally diagnosed with primary papillary serous carcinoma of
the peritoneum (PSCP).
Conclusion: PSCP can present many years after risk-reducing surgery and be difficult to detect.
Surveillance remains the best course of management for patients with known BRCA mutations.
Background
Women with BRCA1 or BRCA2 germ-line mutations are at
an increased risk of developing tumours of the breast,
ovary and peritoneum. The cumulative lifetime risk of
invasive breast cancer for women with either mutation is
between 60–85% whereas this is between 15–65% for
epithelial ovarian cancer [1-3]. Management strategies for
genetically susceptible women include genetic counsel-
ling, chemoprevention, radiological and tumour-marker
surveillance, and risk-reducing surgery such as mastec-
tomy and bilateral salpingo-oophorectomy.
Primary papillary serous carcinoma of the peritoneum
(PSCP) is a rare tumour found predominantly in elderly
and post-menopausal women [4]. It shares many features
with its ovarian analogue, serous ovarian papillary carci-
noma, making diagnosis less than straightforward by both
radiological imaging and histological analysis. Although
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the pathogenesis of PSCP remains unclear, familial stud-
ies have led to the inclusion of peritoneal carcinoma in
the hereditary breast ovarian cancer (HBOC) syndrome,
which also includes Fallopian tube neoplasms [5,6].
The authors present an interesting case of primary perito-
neal cancer. This was diagnosed twenty-seven years after
risk-reducing surgery (ovarian ablation and mastectomy)
for a BRCA1 mutation in the context of breast disease
management. Following investigation for bowel related
symptoms, she was found to have a secondary sigmoid
cancer of indeterminate origin. After undergoing a
laparotomy and resection of this lesion, a diagnosis of
PSCP was reached.
Case presentation
A 33-year old Caucasian woman was diagnosed with ade-
nocarcinoma of the right breast in 1976 following the dis-
covery of a breast lump. She underwent a right-sided
mastectomy without adjuvant therapy. Two years later at
age 35, back pain prompted a bone scan which revealed a
'hot spot' in the region of the lumbar spine. This was
thought to represent spinal metastases and the patient
received local radiotherapy. After counselling for risk-
reducing surgery, the patient chose to undergo a bilateral
salpingo-oophorectomy, but declined a proposed hyster-
ectomy.
There was a strong family history of breast disease with
both her mother and maternal grandmother diagnosed
with breast cancer at 34 years and 41 years, respectively.
There were no other known cancers in her family. In 2004,
aged 62 years, the patient underwent genetic testing,
which uncovered a BRCA1 mutation (185delAG). A pro-
phylactic left-sided mastectomy was subsequently per-
formed.
Aged 64 years, the patient presented complaining of
change in bowel habit, faecal leakage, urgency and left-
sided abdominal discomfort. Examination revealed a ten-
der, palpable fullness in the left iliac fossa. Initial routine
blood tests showed haemoglobin of 11.7 g/dl with a nor-
mal mean cell volume and no abnormalities of electro-
lytes, liver or kidney function. Tumour markers revealed
carcinoembryonic antigen (CEA) 3 ug/L and CA125 3 Ku/
L (both within normal limits). At colonoscopy, a necrotic
lesion was seen in the proximal sigmoid colon. Biopsies
confirmed a very poorly differentiated papillary adenocar-
cinoma of the sigmoid, the immunoprofile of which
favoured ovarian origin rather than colonic; being highly
positive to CK7, while negative to CK20 (Figures 1a and
1b). In addition, there was some faint staining for ER but
PR staining was negative. A staging CT scan excluded mac-
roscopic metastases and reported a large bowel-related
mass measuring 68 mm by 67 mm, contiguous with the
left lateral aspect of the bladder with no associated patho-
logical lymphadenopathy. The radiological appearance
suggested a malignancy of colonic origin.
Laparotomy findings included a bulky tumour adherent
to the left pelvic brim and pelvic side-wall, as well as two
separate peritoneal deposits, one within the pelvis and
one at the terminal ileum. There was no further pathology
noted. The patient underwent an en bloc resection of sig-
moid colon, bladder, omentum, left pelvic side wall and
uterus. The histology of the surgical specimens revealed
peritoneal nodules of poorly differentiated papillary ade-
nocarcinoma (Figures 2a and 2b), a normal atrophic
uterus with no evidence of tumour nor Fallopian tube
remnants, and a poorly differentiated papillary adenocar-
cinoma of the large bowel which penetrated the bowel
wall and had invaded adherent bladder (Figures 3a and
3b). There was associated extramural venous invasion but
no metastatic lymph nodes (total of 3 found). When the
specimens were reviewed in a multidisciplinary setting,
incorporating colorectal surgeons and gynaecologists, it
was concluded that they represented a primary peritoneal
carcinoma of high grade. A post-operative CA125 titre
performed within 2 weeks of the operation was 3 Ku/L
and subsequent titres over the following 4 months were
between 3 and 4 Ku/L. She is currently receiving chemo-
therapy treatment.
Discussion
Mutations in BRCA1  gene (and BRCA2) are associated
with inherited breast and ovarian cancer, although the
exact nature of this tissue specificity is incompletely
understood. The prevalence of mutations of BRCA1 gene
in the general population is between 0.07% and 0.24%
and between 0.14% and 0.22% for BRCA2 although this
is higher in Ashkenazi Jews [7,8]. The risk of primary peri-
toneal carcinoma is also increased in patients carrying
BRCA1 (and BRCA2) mutations with a cumulative life-
time risk of between 1.3–20% [6,9,10]. This is in contrast
with invasion of the peritoneum by carcinomatous metas-
tasis is far more common.
The development of PSCP is thought to originate de novo
from the peritoneal lining of the pelvis and abdomen.
However, it is histologically indistinguishable from its
ovarian analogue and may develop in women years after
a prophylactic oophorectomy [11]. Two theories have
been proposed to explain these similarities. The first sug-
gests that peritoneal carcinoma originates from nests of
ovarian tissue remnants that are left within the perito-
neum during embryonic descent of the female gonads.
The second suggests that both ovarian and peritoneal tis-
sue (with a common mesodermal origin), have mullerian
potential [12,13].World Journal of Surgical Oncology 2007, 5:102 http://www.wjso.com/content/5/1/102
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Diagnosing PSCP can be particularly challenging as most
peritoneal carcinomas present late and are difficult to
detect both clinically and radiologically. There are certain
CT features which are specific to peritoneal disease, but
these are subtle and may only help in differentiating from
other similar lesions such as mesothelioma and metastatic
disease [14]. There is some role for serial tumour marker
measurements (CA-125) but this may be misleading.
Although it is not uncommon to have a low initial CA-
125 titre, this value would be expected to rise following a
debulking procedure. However, this did not occur in our
case.
In the case report the patient had undergone ovarian abla-
tion as a form of risk-reduction surgery during the man-
agement of breast cancer. The genetic associations were
not known at the time but the surgery acted indirectly as
prophylaxis for future ovarian and peritoneal cancer. The
initial dilemmas with this patient were in understanding
the origin of the sigmoid tumour. The clinical picture,
colonoscopy findings and CT images suggested a primary
colonic pathology which was in contrast to the histology
results favouring an ovarian origin. This was made all the
more confusing as the patient had previously undergone
a bilateral salpingo-oophorectomy and serum CA125
titres were normal. The fact that the sigmoid colon had
become a site of tumour spread was not surprising due to
1a)Sigmoid colon biopsy, and 1b) with CK7 stain demonstrating features of ovarian-type adenocarcinoma Figure 1
1a)Sigmoid colon biopsy, and 1b) with CK7 stain demonstrating features of ovarian-type adenocarcinoma.
A) and B) Microphotograph of peritoneal nodules Figure 2
A) and B) Microphotograph of peritoneal nodules.World Journal of Surgical Oncology 2007, 5:102 http://www.wjso.com/content/5/1/102
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the intimate anatomical relationship of peritoneum and
sigmoid colon.
This case highlights the difficulties faced by patients with
BRCA mutations as they are at an increased risk of cancer
from several sources. In addition to the risks of those can-
cers which make up the HBOC syndrome, there have been
lower but significant risks reported for other cancers,
including pancreas and stomach [15,16]. When consider-
ing surgical prophylaxis, bilateral salpingo-oophorectomy
and total hysterectomy is the most effective procedure to
reduce the risk of development of ovarian and peritoneal
carcinoma [17]. The estimated risk reduction is between
80–85% for ovarian, Fallopian tube and peritoneal cancer
[10,18]. It is important to appreciate however, that in the
case described, the patient chose not to have a hysterec-
tomy and that the surgery was performed in the context of
a breast tumour and not ovarian and peritoneal disease.
There may have been retained Fallopian tube remnants
which could have been a potential source of malignancy.
For risk-reduction surgery to be most beneficial in the
context of ovarian, Fallopian tube and peritoneal cancer,
surgery should include bilateral salpingo-oophorectomy
and hysterectomy with the surgical specimens to be exam-
ined in fine detail to exclude the presence of microscopic
disease. The estimated risk for developing PSCP after pro-
phylactic surgery is between 0.5–2% [18-20].
Conclusion
This is the first described case of primary peritoneal carci-
noma presenting as a secondary colonic malignancy many
years after risk-reducing surgery. This diagnosis was
reached following investigation and surgical resection for
symptoms related to the lower gastrointestinal tract.
Despite risk-reducing surgery in the form of prophylactic
mastectomy and bilateral oopherectomy, albeit in the
context of breast cancer, a primary peritoneal serous carci-
noma developed many years later. The authors emphasise
that although risk-reducing surgery has been shown to
confer a clear reduction in risk of developing breast, ovar-
ian and peritoneal carcinoma, the possibility of a late
presentation of peritoneal carcinoma remains.
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